Trevena (TRVN) Competitors $0.97 +0.06 (+6.59%) As of 07/9/2025 02:23 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TRVN vs. LIPO, PALI, ONVO, ADIL, WINT, GENE, EVAX, PPBT, ZVSA, and ENVBShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Lipella Pharmaceuticals (LIPO), Palisade Bio (PALI), Organovo (ONVO), Adial Pharmaceuticals (ADIL), Windtree Therapeutics (WINT), Genetic Technologies (GENE), Evaxion A/S (EVAX), Purple Biotech (PPBT), ZyVersa Therapeutics (ZVSA), and Enveric Biosciences (ENVB). These companies are all part of the "pharmaceutical products" industry. Trevena vs. Its Competitors Lipella Pharmaceuticals Palisade Bio Organovo Adial Pharmaceuticals Windtree Therapeutics Genetic Technologies Evaxion A/S Purple Biotech ZyVersa Therapeutics Enveric Biosciences Lipella Pharmaceuticals (NASDAQ:LIPO) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations. Do institutionals and insiders believe in LIPO or TRVN? 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher valuation & earnings, LIPO or TRVN? Lipella Pharmaceuticals has higher revenue and earnings than Trevena. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K6.82-$5.02M-$4.08-0.20Trevena$443K2.10-$40.29M-$47.04-0.02 Do analysts recommend LIPO or TRVN? Trevena has a consensus price target of $5.00, suggesting a potential upside of 415.46%. Given Trevena's stronger consensus rating and higher possible upside, analysts plainly believe Trevena is more favorable than Lipella Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is LIPO or TRVN more profitable? Trevena has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Trevena's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-988.83% -224.08% -172.88% Trevena N/A N/A -119.55% Does the media refer more to LIPO or TRVN? In the previous week, Trevena had 1 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Lipella Pharmaceuticals. Trevena's average media sentiment score of 1.08 beat Lipella Pharmaceuticals' score of 0.00 indicating that Trevena is being referred to more favorably in the news media. Company Overall Sentiment Lipella Pharmaceuticals Neutral Trevena Positive Which has more volatility and risk, LIPO or TRVN? Lipella Pharmaceuticals has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Comparatively, Trevena has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. SummaryTrevena beats Lipella Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$930K$790.61M$5.55B$8.99BDividend YieldN/A4.84%5.25%4.03%P/E Ratio-0.021.3027.4420.13Price / Sales2.10227.12414.93172.83Price / CashN/A23.4437.0657.97Price / Book-0.096.148.135.61Net Income-$40.29M-$27.58M$3.16B$248.50M7 Day Performance3.19%0.99%2.92%4.36%1 Month Performance-3.96%7.42%3.14%6.87%1 Year Performance-82.72%7.17%33.91%20.78% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena2.4594 of 5 stars$0.97+6.6%$5.00+415.5%-82.0%$930K$443K-0.0240Gap DownLIPOLipella Pharmaceuticals1.5052 of 5 stars$0.85+9.1%N/A-76.7%$3.49M$536.36K-0.214PALIPalisade Bio2.2278 of 5 stars$0.73+1.2%$12.00+1,534.9%-82.8%$3.48M$250K-0.1110News CoverageONVOOrganovoN/AN/AN/AN/A$3.47M$122K-2.4020Gap UpADILAdial Pharmaceuticals2.3743 of 5 stars$0.33-0.4%$8.00+2,357.0%-71.5%$3.41MN/A-0.2220News CoverageGap DownWINTWindtree Therapeutics1.8325 of 5 stars$0.80-14.1%$350.00+43,759.6%-99.6%$3.40MN/A0.0030Gap DownHigh Trading VolumeGENEGenetic TechnologiesN/A$0.77flatN/AN/A$3.37M$7.66M0.0050High Trading VolumeEVAXEvaxion A/S2.3295 of 5 stars$2.30-3.8%$10.00+334.8%-84.7%$3.35M$3.34M-1.9860PPBTPurple Biotech1.8799 of 5 stars$2.44-1.6%$33.00+1,252.5%N/A$3.30MN/A-0.9320ZVSAZyVersa Therapeutics1.0634 of 5 stars$0.66-1.4%N/A-86.5%$3.20MN/A0.002News CoverageENVBEnveric Biosciences2.6031 of 5 stars$1.27+0.8%$10.00+687.4%-80.2%$3.11MN/A-0.0320 Related Companies and Tools Related Companies LIPO Alternatives PALI Alternatives ONVO Alternatives ADIL Alternatives WINT Alternatives GENE Alternatives EVAX Alternatives PPBT Alternatives ZVSA Alternatives ENVB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVN) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
